A citation-based method for searching scientific literature

Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
Times Cited: 60







List of co-cited articles
450 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
48


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
33

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
92
30

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
21

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Urd Kielgast, Meena Asmar, Sten Madsbad, Jens J Holst. J Clin Endocrinol Metab 2010
41
29


Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
18

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
51
19


Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
15

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
717
15


Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Jill Hamilton, Elizabeth Cummings, Vera Zdravkovic, Diane Finegood, Denis Daneman. Diabetes Care 2003
106
15

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
25

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Andrea N Traina, Melinda E Lull, Adrian C Hui, Toni M Zahorian, Jane Lyons-Patterson. Can J Diabetes 2014
33
27

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
939
13

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
185
13


Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Venkat Sasidhar Renukuntla, Neesha Ramchandani, Jeniece Trast, Martin Cantwell, Rubina A Heptulla. J Diabetes Sci Technol 2014
27
29

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
14

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50
16

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
11



Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
121
11

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
37
18

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
783
11

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS One 2008
56
12

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
11

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
11

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
11

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Bernard Zinman, Byron J Hoogwerf, Santiago Durán García, Denái R Milton, Joseph M Giaconia, Dennis D Kim, Michael E Trautmann, Robert G Brodows. Ann Intern Med 2007
345
10


Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
600
10

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
Nicole A Sherry, Wei Chen, Jake A Kushner, Mariela Glandt, Qizhi Tang, Sue Tsai, Pere Santamaria, Jeffrey A Bluestone, Anne-Marie B Brillantes, Kevan C Herold. Endocrinology 2007
138
10

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
John B Buse, Daniel J Drucker, Kristin L Taylor, Terri Kim, Brandon Walsh, Hao Hu, Ken Wilhelm, Michael Trautmann, Larry Z Shen, Lisa E Porter. Diabetes Care 2010
240
10

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
10

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
Margaret T Behme, John Dupré, Thomas J McDonald. BMC Endocr Disord 2003
53
11

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
10


DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
299
10



The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Laurent Meyer, Philip Bohme, Irene Delbachian, Philippe Lehert, Nathalie Cugnardey, Pierre Drouin, Bruno Guerci. Diabetes Care 2002
58
10


The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
35
17

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Stuart A Weinzimer, Jennifer L Sherr, Eda Cengiz, Grace Kim, Jessica L Ruiz, Lori Carria, Gayane Voskanyan, Anirban Roy, William V Tamborlane. Diabetes Care 2012
89
10

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
149
10

Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.
Kristen J Nadeau, Kelsey Chow, Suhyla Alam, Kara Lindquist, Sarah Campbell, Kim McFann, Georgeanna Klingensmith, Phillipe Walravens. Pediatr Diabetes 2015
46
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.